Myasthenia Gravis
📧 Sign up to get email alerts when something new happens for Myasthenia Gravis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-06-22FDA Approved: PYRIDOSTIGMINE BROMIDE — Original Application (Zydus Lifesciences Limited)
FDA approved pyridostigmine bromide from Zydus Lifesciences Limited under an Original Application. The drug is used for symptomatic treatmen…
-
CLINICAL_TRIALS research · 2015-06-15Clinical Trial Update: Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F
This clinical trial update describes translation, cross-cultural adaptation and validation of the MGQOL-15-F questionnaire for patients with…
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Mycophenolate Mofetil in Myasthenia Gravis [Phase 3]
A Phase 3 clinical trial evaluating mycophenolate mofetil for myasthenia gravis has completed.
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis [NA]
This clinical trial update notes that the randomized study of intravenous immunoglobulin in patients with mild or moderate myasthenia gravis…
-
FDA approval · 2015-02-23FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved a supplemental application for pyridostigmine bromide by Oceanside Pharmaceuticals (brand Mestinon).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-01-08FDA Approved: NEOSTIGMINE METHYLSULFATE — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fresenius Kabi USA, LLC's NEOSTIGMINE METHYLSULFATE under an Original Application (NDA).
-
CLINICAL_TRIALS trial_result · 2014-12-15Clinical Trial Update: The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor [Phase 2]
Phase 2 clinical trial evaluating the safety and efficacy of a 3-hole subxiphoid approach for treating anterior mediastinal tumors, includin…
-
FDA approval · 2014-12-11FDA Approved: BLOXIVERZ — Supplemental Application (Exela Pharma Sciences, LLC)
FDA approved a supplemental application for BLOXIVERZ (neostigmine methylsulfate) from Exela Pharma Sciences, LLC.
-
FDA approval · 2014-09-30FDA Approved: BLOXIVERZ — Supplemental Application (Exela Pharma Sciences, LLC)
FDA approved a supplemental application for BLOXIVERZ (neostigmine methylsulfate) from Exela Pharma Sciences, LLC.
-
FDA label_change · 2014-09-30FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved a supplemental application for pyridostigmine bromide by Oceanside Pharmaceuticals, updating the product's labeling.
-
CLINICAL_TRIALS trial_result · 2014-08-25Clinical Trial Update: FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients [Phase 3]
Phase 3 trial of FK506 (tacrolimus) for steroid non-resistant myasthenia gravis has completed.
-
FDA approval · 2014-07-25FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved a supplemental application for pyridostigmine bromide submitted by Oceanside Pharmaceuticals, resulting in updated labeling und…
-
FDA approval · 2014-06-18FDA Approved: BLOXIVERZ — Supplemental Application (Exela Pharma Sciences, LLC)
FDA approved a supplemental application for BLOXIVERZ (neostigmine methylsulfate) from Exela Pharma Sciences, LLC.
-
FDA label_change · 2014-05-16FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Oceanside Pharmaceuticals)
The FDA approved a supplemental application for pyridostigmine bromide from Oceanside Pharmaceuticals, indicating a labeling or regulatory u…
-
CLINICAL_TRIALS research · 2014-04-28Clinical Trial Update: National Registry for Egyptian Pediatric Neuromuscular Diseases
This document provides an update on Egypt's National Registry for Pediatric Neuromuscular Diseases, cataloging Spinal Muscular Atrophy, Musc…
-
FDA approval · 2014-01-09FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved a supplemental application for pyridostigmine bromide from Oceanside Pharmaceuticals.
-
FDA approval · 2014-01-03FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Surgeon General-Department of the Army (TSG-DA))
FDA has approved a supplemental application for pyridostigmine bromide, submitted by the Surgeon General of the Department of the Army.
-
FDA approval · 2014-01-03FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Oceanside Pharmaceuticals)
The FDA approved Oceanside Pharmaceuticals' supplemental application for pyridostigmine bromide.
-
FDA approval · 2013-09-26FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Oceanside Pharmaceuticals)
The FDA approved a supplemental application for pyridostigmine bromide submitted by Oceanside Pharmaceuticals.
-
FDA approval · 2013-07-22FDA Approved: REGONOL — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for Regonol (pyridostigmine bromide) submitted by Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: A Pilot Trial of Rituxan in Refractory Myasthenia Gravis [Phase 1, Phase 2]
This update reports the completion of a Phase 1/2 pilot trial of rituximab (Rituxan) in patients with refractory myasthenia gravis. The stud…
-
CLINICAL_TRIALS trial_result · 2012-12-11Clinical Trial Update: Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis [Phase 2]
This clinical trial update reports on a Phase 2 study of Rituximab for refractory inflammatory myopathies and refractory myasthenia gravis, …
-
CLINICAL_TRIALS trial_result · 2012-03-15Clinical Trial Update: A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis [EARLY_Phase 1]
This is a pilot, early-phase 1 clinical trial evaluating granulocyte-macrophage colony-stimulating factor (GM-CSF) in generalized Myasthenia…
-
CLINICAL_TRIALS research · 2011-11-10Clinical Trial Update: Perception and Multisensory Integration in Neurological Patients Using fMRI [NA]
An update on a brain-imaging clinical study investigating perception and multisensory integration in neurological patients using fMRI across…
-
FDA approval · 2010-10-28FDA Approved: PYRIDOSTIGMINE BROMIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for pyridostigmine bromide from Amneal Pharmaceuticals of New York LLC.